Dyne Therapeutics, Inc. Payments to Acquire Marketable Securities
Dyne Therapeutics, Inc. (DYN) reported Payments to Acquire Marketable Securities of $107.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-29
- Dyne Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $42.79M, a 4.53% increase year-over-year.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $64.28M, a 2.56% decline year-over-year.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $26.71M, a 49.33% decline year-over-year.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $46.92M, a 17.74% decline year-over-year.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $180.53M, a 43.13% decline from fiscal 2024.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $317.44M, a 617.19% increase from fiscal 2023.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $44.26M, a 63.47% decline from fiscal 2022.
- Dyne Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $121.18M, a 48.81% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $107.06M 10-Q · filed 2026-07-29 | $133.78M derived: sum of 3 quarters · filed 2026-07-29 | $180.69M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $64.28M 10-Q · filed 2026-05-11 | $90.99M derived: sum of 2 quarters · filed 2026-05-11 | $137.91M derived: sum of 3 quarters · filed 2026-05-11 | $178.84M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $26.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $73.63M derived: sum of 2 quarters · filed 2026-03-02 | $114.56M derived: sum of 3 quarters · filed 2026-07-29 | $180.53M 10-K · filed 2026-03-02 |
| 2025-09-30 | $46.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $87.85M derived: sum of 2 quarters · filed 2026-07-29 | $153.82M 10-Q · filed 2025-11-05 | $206.54M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $40.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $106.90M 10-Q · filed 2026-07-29 | $159.62M derived: sum of 3 quarters · filed 2026-07-29 | $216.66M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $65.97M 10-Q · filed 2026-05-11 | $118.68M derived: sum of 2 quarters · filed 2026-05-11 | $175.72M derived: sum of 3 quarters · filed 2026-05-11 | $202.03M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $52.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $109.75M derived: sum of 2 quarters · filed 2026-03-02 | $136.06M derived: sum of 3 quarters · filed 2026-03-02 | $317.44M 10-K · filed 2026-03-02 |
| 2024-09-30 | $57.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $83.34M derived: sum of 2 quarters · filed 2025-11-05 | $264.73M 10-Q · filed 2025-11-05 | $264.73M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $26.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $207.69M 10-Q · filed 2025-07-28 | $207.69M derived: sum of 3 quarters · filed 2026-03-02 | $217.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $181.39M 10-Q · filed 2025-05-08 | $181.39M derived: sum of 2 quarters · filed 2026-03-02 | $190.96M derived: sum of 3 quarters · filed 2026-03-02 | $208.96M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.58M derived: sum of 2 quarters · filed 2026-03-02 | $27.57M derived: sum of 3 quarters · filed 2026-03-02 | $44.26M 10-K · filed 2026-03-02 |
| 2023-09-30 | $9.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $27.57M derived: sum of 2 quarters · filed 2024-11-12 | $44.26M 10-Q · filed 2024-11-12 | $70.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $34.68M 10-Q · filed 2024-08-12 | $61.15M derived: sum of 3 quarters · filed 2025-02-27 | $66.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $16.69M 10-Q · filed 2024-05-02 | $43.15M derived: sum of 2 quarters · filed 2025-02-27 | $48.33M derived: sum of 3 quarters · filed 2025-02-27 | $82.54M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $26.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $31.65M derived: sum of 2 quarters · filed 2025-02-27 | $65.85M derived: sum of 3 quarters · filed 2025-02-27 | $121.18M 10-K · filed 2025-02-27 |
| 2022-09-30 | $5.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $39.38M derived: sum of 2 quarters · filed 2023-10-30 | $94.71M 10-Q · filed 2023-10-30 | $123.23M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $34.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $89.53M 10-Q · filed 2023-08-03 | $118.04M derived: sum of 3 quarters · filed 2023-08-03 | $169.69M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $55.33M 10-Q · filed 2023-05-11 | $83.84M derived: sum of 2 quarters · filed 2023-05-11 | $135.49M derived: sum of 3 quarters · filed 2023-05-11 | $159.86M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $28.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $80.16M derived: sum of 2 quarters · filed 2023-03-02 | $104.53M derived: sum of 3 quarters · filed 2023-03-02 | $236.72M 10-K · filed 2023-03-02 |
| 2021-09-30 | $51.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $76.02M derived: sum of 2 quarters · filed 2022-11-03 | $208.21M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $24.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $156.56M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $132.19M 10-Q · filed 2022-05-02 | |||
| 2020-12-31 | $44.50M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |